I confirm that the above details are correct:

Signed: Date:

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

August 2025

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:			
Name:	Name:			
Ward:	NHI:			
Voriconazole				
INITIATION – Proven or probable aspergillus infection Prerequisites (tick boxes where appropriate)				
O Prescribed by, or recommended by a clinical microbiologist, haema guideline that has been endorsed by the Health NZ Hospital.	tologist or infectious disease specialist, or in accordance with a protocol or			
Patient is immunocompromised and Patient has proven or probable invasive aspergillus infection				
INITIATION – Possible aspergillus infection Prerequisites (tick boxes where appropriate)				
O Prescribed by, or recommended by a clinical microbiologist, haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.				
O Patient is immunocompromised				
Patient has possible invasive aspergillus infection				
A multidisciplinary team (including an infectious disease physical)	sician) considers the treatment to be appropriate			
INITIATION – Resistant candidiasis infections and other moulds Prerequisites (tick boxes where appropriate)				
Prescribed by, or recommended by a clinical microbiologist, haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and				
Patient is immunocompromised and				
O Patient has fluconazole resistant candidiasis or				
Patient has mould strain such as Fusarium spp. and S	cedosporium spp			
A multidisciplinary team (including an infectious disease physical)	sician or clinical microbiologist) considers the treatment to be appropriate			
INITIATION – Invasive fungal infection prophylaxis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)				
O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.				
O The patient is at risk of invasive fungal infection and				
Voriconazole is prescribed by, or recommended by a hapaediatric haematologist or paediatric oncologist	aematologist, transplant physician, infectious disease specialist,			
O Prescribing voriconazole is in accordance with a protoc	ol or guideline that has been endorsed by the Health New Zealand - Te is a greater than 10% risk of invasive fungal infection (IFI)			

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

August 2025

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER			PATIENT:		
:				Name:	
				NHI:	
Voriconazole - continued					
Prerequisites (tick boxes where appropriate)					
O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.					
The patient is at risk of invasive fungal infection					
	or (0	Voriconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist		
		0		or guideline that has been endorsed by the Health New Zealand - Te s a greater than 10% risk of invasive fungal infection (IFI)	
	cona TINUA ssess equis	conazole TINUATIO ssessment equisites NZ He	CONAZOIE - consistent requisites (tick by Prescribed NZ Hospita) The pand	TINUATION – Invasive fungal infection prophylaxis seessment required after 6 months equisites (tick boxes where appropriate) Prescribed by, or recommended by any relevant practitioner, or in acc NZ Hospital. The patient is at risk of invasive fungal infection and Voriconazole is prescribed by, or recommended by a hae paediatric haematologist or paediatric oncologist	